Amundi Acquires 13,041 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Amundi raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 243.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,402 shares of the company’s stock after purchasing an additional 13,041 shares during the period. Amundi’s holdings in Harmony Biosciences were worth $635,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares during the period. Mendota Financial Group LLC raised its position in shares of Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after buying an additional 965 shares in the last quarter. KBC Group NV raised its position in shares of Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Harmony Biosciences in the third quarter worth $74,000. Finally, PNC Financial Services Group Inc. raised its position in Harmony Biosciences by 28.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after purchasing an additional 519 shares in the last quarter. 86.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Harmony Biosciences

In other news, CFO Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey M. Dayno sold 19,293 shares of Harmony Biosciences stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,452 shares of company stock valued at $2,831,679. 30.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HRMY. Mizuho raised their price target on Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday, February 25th. HC Wainwright lowered their price target on Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $53.33.

Harmony Biosciences Stock Up 1.5 %

NASDAQ HRMY opened at $34.90 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock has a market capitalization of $2.00 billion, a PE ratio of 16.54, a PEG ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The business’s 50-day moving average is $36.39 and its 200 day moving average is $35.60.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.11. The company had revenue of $201.30 million for the quarter, compared to analysts’ expectations of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the firm earned $0.45 earnings per share. Sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.